Financial Results as on 31.03.2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Vaxfab Enterprises reported audited results for FY26, with standalone revenue from operations rising to ₹9,410.75 lakhs (from ₹5,867.10 lakhs) and standalone profit after tax jumping to ₹363.80 lakhs (from ₹58.42 lakhs), translating to an EPS of ₹4.33. However, the consolidated picture is sharply weaker — the company swung to a consolidated loss after tax of ₹(463.08) lakhs versus a profit of ₹78.31 lakhs in the prior year, on consolidated revenue of ₹13,126.29 lakhs. Crucially, the statutory auditor (Chandabhoy & Jassoobhoy) issued a Disclaimer of Opinion on both the standalone and consolidated results, citing inadequate books, missing debtor/creditor confirmations, unsecured loans without formal agreements, and non-maintenance of MSMED creditor records — largely blamed on the previous management. The company's board outcome letter incorrectly described the audit opinion as 'unmodified,' which contradicts the actual auditor's report. Total assets grew sharply to ₹17,260.97 lakhs (standalone), driven mainly by a surge in trade receivables to ₹10,686.49 lakhs from ₹2,092.26 lakhs.
Despite strong headline standalone profit growth, the auditor's disclaimer means the reported numbers cannot be relied upon as giving a true and fair view, and the company's own filing misstated the audit opinion as 'unmodified.' The consolidated loss and the red flags around record-keeping, unconfirmed receivables, and weak disclosures make this a high-risk filing — shareholders should treat the earnings numbers with significant caution.